Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

9.2K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modulating the Rate of Charge Recombination in Bichromophore End-Capped Hairpin DNA Sequences.

The journal of physical chemistry letters·2026
Same author

CPEB3 selectively inhibits α-synuclein aggregation without modulating TDP-43 pathology.

FEBS letters·2026
Same author

Phosphorylation of α‑Synuclein Fibrils at S129 Changes DNAJB1 Binding as Probed by Solid-State NMR.

JACS Au·2026
Same author

Photothermally Powered Wearable Thermal Battery Through Segmental Polymer Motion-Driven, Solid-Solid Phase Change with Durable and High Energy Density.

Small (Weinheim an der Bergstrasse, Germany)·2025
Same author

Glycated Alpha-Synuclein Assemblies Cause Distinct Parkinson's Disease Pathogenesis in Mice.

ACS chemical neuroscience·2025
Same author

Exploring the Structural Order of Condensates Formed by the PRD2 Domain of Mouse CPEB3.

ACS chemical neuroscience·2025

Related Experiment Video

Updated: May 29, 2025

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.3K

Exploring the Potential Interaction between the Functional Prion Protein CPEB3 and the Amyloidogenic Pathogenic

Ann Teres Babu1, Arshad Abdul Vahid1, Dhanya S Reselammal1

  • 1School of Chemistry, Indian Institute of Science Education and Research Thiruvananthapuram (IISER TVM), Vithura, Thiruvananthapuram 695551, India.

The Journal of Physical Chemistry. B
|February 5, 2025
PubMed
Summary

The prion domain of CPEB3 protein inhibits tau protein aggregation, a key factor in Alzheimer's disease. This discovery suggests a potential therapeutic strategy using Poly-Q peptides for Alzheimer's disease treatment.

More Related Videos

Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans
12:57

Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans

Published on: January 8, 2015

15.8K
In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening
09:49

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

18.5K

Related Experiment Videos

Last Updated: May 29, 2025

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.3K
Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans
12:57

Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans

Published on: January 8, 2015

15.8K
In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening
09:49

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

18.5K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Molecular Biology

Background:

  • Abnormal tau protein aggregation is a hallmark of Alzheimer's disease.
  • The prion-like RNA-binding protein (RBP) CPEB3 aggregates functionally, aiding long-term memory formation.
  • The interaction between tau and CPEB3 in relation to disease and memory remains unexplored.

Purpose of the Study:

  • To investigate the interaction between CPEB3 and tau protein.
  • To determine if CPEB3 can modulate tau aggregation.
  • To identify potential therapeutic targets for Alzheimer's disease based on this interaction.

Main Methods:

  • Residue-specific NMR relaxation studies were employed.
  • The interaction between the first prion domain of CPEB3 (PRD1) and tau-K18 was analyzed.
  • The inhibitory effects of PRD1 subdomains and a synthesized Poly-Q peptide on tau-K18 aggregation were assessed.

Main Results:

  • The PRD1 domain of CPEB3 directly interacts with the VQIVYKPVDLSKV segment of tau.
  • This interaction effectively inhibits the aggregation of tau-K18.
  • The PRD1-Q region of CPEB3 was identified as crucial for inhibiting tau-K18 aggregation.
  • A 15-amino acid Poly-Q peptide was synthesized and demonstrated to inhibit tau-K18 aggregation.

Conclusions:

  • CPEB3's PRD1 domain interacts with tau, preventing pathological aggregation.
  • The PRD1-Q region is key to this inhibitory effect.
  • Synthesized Poly-Q peptides show promise as potential therapeutic agents for Alzheimer's disease.